PURPOSE: The outcome of a prospective case series of 47 patients with newly diagnosed resectable locoregionally advanced oropharyngeal squamous cell carcinoma treated with platinum-based induction-concurrent chemoradiotherapy (IC/CCRT) was compared with the outcome of 47 matched historical control patients treated with surgery and postoperative RT. METHODS AND MATERIALS: A total of 47 control patients with locoregionally advanced oropharyngeal squamous cell carcinoma were identified from review of a prospectively compiled comprehensive computerized head-and-neck cancer database and were matched with a prospective case series of patients undergoing IC/CCRT by disease stage, nodal status, gender, and age (± 5 years). The IC/CCRT regimen consisted of one cycle of induction chemotherapy followed by conventionally fractionated RT to a total dose of 66-70 Gy concomitantly with two cycles of chemotherapy. Each cycle of chemotherapy consisted of cisplatinum, 100 mg/m(2), and a continuous infusion of 5-fluorouracil, 1,000 mg/m(2)/d for 5 days. The survival analysis was performed using Kaplan-Meier estimates. Matched-pair survival was compared using the Cox proportional hazards model. RESULTS: No significant difference was found in the overall survival or progression-free survival rates between the two groups. The matched analysis of survival did not show a statistically significant greater hazard ratio for overall death (hazard ratio, 1.35; 95% confidence interval, 0.65-2.80; p = .415) or progression (hazard ratio, 1.44; 95% confidence interval, 0.72-2.87; p = .301) for patients undergoing IC/CCRT. CONCLUSION: Although the sample size was small and not randomized, this matched-pair comparison between a prospective case series and a historical cohort treated at the same institution showed that the efficacy of IC/CCRT with salvage surgery is as good as primary surgical resection and postoperative RT.
PURPOSE: The outcome of a prospective case series of 47 patients with newly diagnosed resectable locoregionally advanced oropharyngeal squamous cell carcinoma treated with platinum-based induction-concurrent chemoradiotherapy (IC/CCRT) was compared with the outcome of 47 matched historical control patients treated with surgery and postoperative RT. METHODS AND MATERIALS: A total of 47 control patients with locoregionally advanced oropharyngeal squamous cell carcinoma were identified from review of a prospectively compiled comprehensive computerized head-and-neck cancer database and were matched with a prospective case series of patients undergoing IC/CCRT by disease stage, nodal status, gender, and age (± 5 years). The IC/CCRT regimen consisted of one cycle of induction chemotherapy followed by conventionally fractionated RT to a total dose of 66-70 Gy concomitantly with two cycles of chemotherapy. Each cycle of chemotherapy consisted of cisplatinum, 100 mg/m(2), and a continuous infusion of 5-fluorouracil, 1,000 mg/m(2)/d for 5 days. The survival analysis was performed using Kaplan-Meier estimates. Matched-pair survival was compared using the Cox proportional hazards model. RESULTS: No significant difference was found in the overall survival or progression-free survival rates between the two groups. The matched analysis of survival did not show a statistically significant greater hazard ratio for overall death (hazard ratio, 1.35; 95% confidence interval, 0.65-2.80; p = .415) or progression (hazard ratio, 1.44; 95% confidence interval, 0.72-2.87; p = .301) for patients undergoing IC/CCRT. CONCLUSION: Although the sample size was small and not randomized, this matched-pair comparison between a prospective case series and a historical cohort treated at the same institution showed that the efficacy of IC/CCRT with salvage surgery is as good as primary surgical resection and postoperative RT.
Authors: P Boscolo-Rizzo; A Del Mistro; F Bussu; V Lupato; L Baboci; G Almadori; M C DA Mosto; G Paludetti Journal: Acta Otorhinolaryngol Ital Date: 2013-04 Impact factor: 2.124
Authors: Dina Oksen; Patricia Prince; Emmanuelle Boutmy; Elizabeth M Garry; Barbara Ellers-Lenz; Adina Estrin; Andreas Johne; Patrice Verpillat; Nicolle M Gatto Journal: Clin Transl Sci Date: 2022-06-11 Impact factor: 4.438
Authors: Paolo Boscolo-Rizzo; Maria Cristina Da Mosto; Enrica Rampazzo; Silvia Giunco; Annarosa Del Mistro; Anna Menegaldo; Lorena Baboci; Monica Mantovani; Giancarlo Tirelli; Anita De Rossi Journal: Cancer Metastasis Rev Date: 2016-09 Impact factor: 9.264
Authors: Anurag K Singh; Christina Mimikos; Adrienne Groman; Shiva Dibaj; Alexis J Platek; David M Cohan; Wesley L Hicks; Vishal Gupta; Hassan Arshad; Moni A Kuriakose; Graham W Warren; Mary E Platek Journal: Oncotarget Date: 2017-08-10
Authors: Matti Sievert; Florian Stelzle; Marc Aubreville; Sarina K Mueller; Markus Eckstein; Nicolai Oetter; Andreas Maier; Konstantinos Mantsopoulos; Heinrich Iro; Miguel Goncalves Journal: Eur Arch Otorhinolaryngol Date: 2021-02-13 Impact factor: 2.503